Ionis Pharmaceuticals
IONS
362 hedge funds and large institutions have $6.17B invested in Ionis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 123 increasing their positions, 128 reducing their positions, and 49 closing their positions.
75% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $27.5M
2% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 49
0% less funds holding
Funds holding: 363 → 362 (-1)
4% less repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 128
1.8% less ownership
Funds ownership: 99.36% → 97.56% (-1.8%)
14% less capital invested
Capital invested by funds: $7.21B → $6.17B (-$1.04B)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$51.4M |
| 2 |
BlackRock
New York
|
+$34.1M |
| 3 |
Squarepoint
New York
|
+$32.7M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
+$20.9M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$43.9M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$43.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$39.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$36.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.9M |
IONS Hedge Fund Activity: Q1 2024 in Review
362 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2024, worth a combined $6.17B — down 14% from $7.21B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new IONS positions and 49 closed out — a net gain of 1 holder — while 123 added to existing stakes and 128 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $51.4M. The largest seller was First Trust Advisors, cutting an estimated $43.9M.
- 362 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2024, down from 363 in Q4 2023.
- Funds reported $6.17B of Ionis Pharmaceuticals stock for Q1 2024, down 14% quarter-over-quarter.
- 50 funds opened new Ionis Pharmaceuticals positions in Q1 2024 and 49 closed out, a net change of +1 holder.
- The largest Ionis Pharmaceuticals buyer in Q1 2024 was Wellington Management Group, an estimated $51.4M added.
- The largest Ionis Pharmaceuticals seller in Q1 2024 was First Trust Advisors, an estimated $43.9M sold.
Based on aggregated 13F filings for Q1 2024.